• A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

  NCT03123471

  CompletedInterventionalPhase 3Updated May 13, 2020
• A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life

  NCT03774875

  CompletedInterventionalPhase 4Updated Jul 10, 2025
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

  NCT03721172

  CompletedInterventionalPhase 3Updated May 29, 2024
• Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

  NCT01232283

  CompletedInterventionalPhase 3Updated Mar 15, 2022
• Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

  NCT01194219

  CompletedInterventionalPhase 3Updated Mar 15, 2022
• A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

  NCT02425826

  CompletedInterventionalPhase 4Updated Jun 5, 2023

ClinicalTrials.gov ID

NCT03553433

Lead Sponsor

University of ZurichOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 4

Enrollment

90Estimated

Last Update Posted

Jun 12, 2018Actual

Start Date

Jun 2018Estimated

Primary Completion Date

Dec 2019Estimated

Completion Date

Jun 2020Estimated

Official Title

A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis

Brief Summary

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

Detailed Description

The scalp is the most frequently affected body region in psoriasis. Scalp Psoriasis can impair the quality of life greatly due to pruritus. This is however not usually investigated as a primary outcome of treatments.

This study will investigate the effects of apremilast on the pruritus and quality of life and other patient reported outcomes in patients with scalp psoriasis.

• Psoriasis of Scalp
• Psoriasis Vulgaris

• Apremilast 30mg
• Placebo Oral Tablet

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion criteria:

1. Adult (>18yrs);
2. Signed informed consent
3. Clinical diagnosis of chronic plaque psoriasis for at least 3 months as determined by the subject's medical history and confirmation of diagnosis through physical examination by the Investigator;
4. Psoriatic lesions with DLQI >10 and involvement of >20% of the scalp and pruritus with a VAS score of > 50 (0-100);
5. Candidate for systemic therapy;
6. Females who are of child-bearing potential should be practicing birth control throughout the study and for 70 days after the last dose of study drug;
7. Subject is judged to be in good health as determined by the Investigator based upon the results of medical history, laboratory profile and physical examination.
8. Creatinine < 80 umol/l at Inclusion

Exclusion criteria:

1. Erythrodermic Ps, medication-induced or medication-exacerbated Ps or new onset guttate Ps or other skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluations of the effect of the investigational product on Ps;

2. Use of any anti-psoriatic therapy last administered less than 4 weeks of start of study drug such as

   1. Three months or 5 PK half-lives, whichever is longer, for biologics tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23/17 inhibitors or other biologic drugs
   2. 4 weeks for immunosuppressive / -modulating drugs including cyclosporine A, methotrexate, azathioprine, mycophenolate mofetil, fumaric acid esters, retinoids, JAK inhibitors, corticosteroids, any other experimental drug, etc.
   3. Topical medications (eg. Corticosteroids) except coal tar shampoo, and/or salicylic acid scalp preparations on scalp lesions.
   4. 4 weeks for phototherapy (ie, UVB, PUVA).

3. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit;

4. Positive serology for hepatitis B, hepatitis C, HIV indicating acute or chronic infection;

5. Chronic recurring bacterial infections or active TB;

6. Positive pregnancy test at Screening or at the Baseline visit;

7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;

8. History of clinically significant alcohol or drug abuse in the last 12 months;

9. Known hypersensitivity to the excipients of Otezla® as stated in the label;

10. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

11. Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

University of ZurichOTHER

nikhil.yawalkar@insel.ch+41 (31) 632 22 88

curdin.conrad@chuv.ch+41 21 314 0400